Analyst Price Targets — CDNA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 9:01 pm | Sung Ji Nam | BTIG | $26.00 | $18.46 | StreetInsider | CareDx, Inc (CDNA) PT Raised to $26 at BTIG |
| January 6, 2026 12:43 pm | — | Craig-Hallum | $26.00 | $19.81 | TheFly | CareDx downgraded to Hold from Buy at Craig-Hallum |
| December 15, 2025 11:25 am | Brandon Couillard | Wells Fargo | $18.00 | $20.57 | TheFly | CareDx price target raised to $18 from $14 at Wells Fargo |
| March 3, 2025 11:13 am | — | H.C. Wainwright | $25.00 | $21.13 | TheFly | CareDx price target lowered to $25 from $26 at H.C. Wainwright |
| November 5, 2024 10:13 am | Sung Ji Nam | BTIG | $35.00 | $22.90 | StreetInsider | CareDx, Inc (CDNA) PT Lowered to $35 at BTIG |
| August 19, 2024 7:50 am | Mark Massaro | BTIG | $40.00 | $33.00 | TheFly | CareDx upgraded to Buy from Neutral at BTIG |
| August 16, 2024 3:05 pm | Bill Bonello | Craig-Hallum | $40.00 | $32.98 | TheFly | CareDx price target raised to $40 from $32 at Craig-Hallum |
| August 1, 2024 8:23 am | Bill Bonello | Craig-Hallum | $32.00 | $19.99 | TheFly | CareDx price target raised to $32 from $22 at Craig-Hallum |
| April 17, 2024 2:04 pm | Mason Carrico | Stephens | $15.00 | $8.29 | StreetInsider | Stephens Reiterates Overweight Rating on CareDx, Inc (CDNA) |
| February 6, 2023 9:50 am | — | Goldman Sachs | $29.00 | $16.26 | Benzinga | Goldman Sachs Maintains Buy on CareDx, Lowers Price Target to $29 |
Latest News for CDNA
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the…
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The transaction, approved by both companies' boards, is expected to close by the end of the third quarter of 2026.
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx's ‘lab products' portfolio creates new opportunities for growth and innovation in the fast growing transplant diagnostics market Acceleration of Eurobio's strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader Creation of a global leading provider of kits for transplantation…
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific for…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CDNA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.